Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(21/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(21/week)
News
United States
(578/week)
Manufacturing
(398/week)
Energy
(304/week)
Technology
(413/week)
Environment
(238/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Bruton's tyrosine kinase
May 23, 2020
New Late-Breaking Data at EAN Indicate Evobrutinib is the First BTK Inhibitor to Report Efficacy and Safety in MS Over 108 Weeks
Apr 27, 2020
Innovent Announces First Patient Dosed in a Pivotal Trial of Parsaclisib in Patients with Indolent Lymphoma in China
Apr 21, 2020
U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
Apr 21, 2020
IMBRUVICA® (ibrutinib) Receives 11th FDA Approval
Apr 07, 2020
Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 for the Treatment of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in China
Jan 08, 2020
New Treatment Approved in Canada for Most Common Type of Leukemia
Dec 08, 2019
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
Dec 07, 2019
More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unresponsive to Prior Regimen
Dec 07, 2019
Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Nov 08, 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Nov 08, 2019
AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia
Nov 06, 2019
Eli Lilly and Company to Present Multiple Abstracts for LOXO-305 at ASH 2019
Oct 09, 2019
Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM)
Oct 08, 2019
Health Canada approves CALQUENCE® (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma (MCL)
Sep 10, 2019
EMD Serono Initiates Pivotal Phase III Program for Investigational Evobrutinib in Relapsing Multiple Sclerosis
Jul 08, 2019
Calquence (acalabrutinib; AstraZeneca/Acerta) Markets, 2017-2026: A Novel, Orally Available, Second-Generation Bruton's Tyrosine Kinase Inhibitor with Potential Antineoplastic Activity
Jul 08, 2019
Zanubrutinib (BeiGene) Drug Overview and Product Profiles 2017-2026
May 10, 2019
Positive Phase II Data Further Highlights Clinical Proof of Concept for Evobrutinib, First Oral Bruton's Tyrosine Kinase (BTK) Inhibitor to Report Positive Phase II Clinical Results in MS
Jan 07, 2019
Lilly Announces Agreement To Acquire Loxo Oncology
Nov 26, 2018
Two Posters on DB102 (Enzastaurin) Presented at the American Society of Hematology Annual Meeting
Page 1
››
Latest News
Apr 25, 2024
Helix Reports First Quarter 2024 Results
Apr 25, 2024
Mativ Announces Appointment of New Chair of its Board of Directors
Apr 25, 2024
Leading Industry Publication: Black & Veatch Remains Among Global Critical Infrastructure Leaders as...
Apr 25, 2024
WM Announces First Quarter 2024 Earnings
Apr 25, 2024
Oceaneering Reports First Quarter 2024 Results
Apr 25, 2024
NewMarket Corporation Reports First Quarter 2024 Results
Apr 25, 2024
Orion S.A. Earns Platinum Sustainability Rating by EcoVadis
Apr 25, 2024
Virginia American Water Finalizes Acquisition of Town of Cape Charles Water and Wastewater Systems
View all News
Agenda
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
21
May
Paris Marriott Rive Gauche & Conference Center
Future Artillery, 21-23 May 2024, Paris Marriott Rive Gauche & Conference Center, France
DELIVERING FIRES IN THE MULTI-DOMAIN BATTLESPACE As artillery reasserts itself as the ‘King of Battlefield’ in the wake...
21
May
United Arab Emirates
ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR Abu Dhabi 2024, 21-23 May 2024, ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR ACCELERATING TRANSFORMATION IN THE NATIONAL SECURITY ECOSYSTEM ISNR Abu Dhabi is the region’s most trusted...
View All Events